Letrozole in Stimulated IVF Cycles
Subfertility
About this trial
This is an interventional treatment trial for Subfertility focused on measuring Subfertility, In-vitro fertilization, Letrozole
Eligibility Criteria
Inclusion Criteria:
- women under 42 years of age
- medical indication for IVF treatment
- antral follicle count prior to ovarian stimulation >=3
- informed consent
Exclusion Criteria:
- women using donor oocytes
- women undergoing preimplantation genetic diagnosis
- women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram
- women with hydrosalpinges shown on scanning and not corrected
- previous documented poor response (<=3 oocytes) to ovarian stimulation using at least FSH 225 IU daily
Sites / Locations
- Department of Obstetrics and Gynaecology
- Peking University Third Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Letrozole group
Control group
Letrozole + standard treatment: Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
Standard treatment: Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration.